Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2016, Article ID 2967578, 11 pages
Review Article

Challenges in the Diagnosis and Management of Growth Hormone Deficiency in India

1Providence Endocrine and Diabetes Specialty Centre, Thiruvananthapuram, Kerala, India
2Lead Endocrinology, Global Medical, Safety and CMO, Merck, Darmstadt, Germany
3Centre for Diabetes and Endocrine Care, Bangalore, Karnataka, India
4Biopharma, NDD and Endocrinology, Merck Specialties Pvt. Ltd., Mumbai, India

Received 13 April 2016; Accepted 15 September 2016

Academic Editor: Darío A. Castroviejo

Copyright © 2016 Mathew John et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


In clinical practice, every year approximately 150,000 children are referred with short stature (SS) based on a cut-off of fifth percentile. The most important endocrine and treatable cause of SS is growth hormone deficiency (GHD). The lack of reliable data on the prevalence of GHD in India limits estimation of the magnitude of this problem. The diagnosis and treatment of GHD are hurdled with various challenges, restricting the availability of growth hormone (GH) therapy to only a very limited segment of the children in India. This review will firstly summarize the gaps and challenges in diagnosis and treatment of GHD based on literature analysis. Subsequently, it presents suggestions from the members at advisory board meetings to overcome these challenges. The advisory board suggested that early initiation of the therapy could better the chances of achieving final adult height within the normal range for the population. Education and awareness about growth disorders among parents, regular training for physicians, and more emphasis on using the Indian growth charts for growth monitoring would help improve the diagnosis and treatment of children with GHD. Availability of an easy-to-use therapy delivery system could also be beneficial in improving adherence and achieving satisfactory outcomes.